NASDAQ:SCYX
SCYNEXIS Stock News
$2.62
-0.150 (-5.42%)
At Close: May 20, 2024
SCYNEXIS, Inc. (SCYX) CEO Marco Taglietti on Q3 2021 Results - Earnings Call Transcript
11:37am, Wednesday, 10'th Nov 2021
SCYNEXIS, Inc. (SCYX) CEO Marco Taglietti on Q3 2021 Results - Earnings Call Transcript
Scynexis (SCYX) Reports Q3 Loss, Tops Revenue Estimates
11:28am, Wednesday, 10'th Nov 2021
Scynexis (SCYX) delivered earnings and revenue surprises of 92.41% and 3.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
SCYNEXIS to Provide a Corporate Update and Report Third Quarter 2021 Financial Results on November 10
08:30am, Wednesday, 03'rd Nov 2021
JERSEY CITY, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan
JERSEY CITY, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan
JERSEY CITY, N.J., Oct. 11, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan
Subpopulation analysis of 74 patients from ongoing Phase 3 FURI study demonstrated similar efficacy against multiple serious fungal infections Subpopulation analysis of 74 patients from ongoing Phase
Analysis of subpopulations from a total of 74 patients evaluated to date from FURI includes outcomes by disease, bone and joint infections, and mouth and throat candidiasis Analysis of subpopulations
Submission is part of the Hansoh Pharma licensing agreement and strategic partnership to research, develop and commercialize ibrexafungerp in the Greater China region Submission is part of the Hansoh
SCYNEXIS Reports Second Quarter 2021 Financial Results and Provides Corporate Update
08:00am, Monday, 16'th Aug 2021
JERSEY CITY, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan
SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Monday, 02'nd Aug 2021
JERSEY CITY, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resista
Scynexis: Leading The Yeast Infection Treatment Industry
02:07am, Tuesday, 27'th Jul 2021
SCYNEXIS lead drug candidate BREXAFEMME recently got FDA approval for the treatment of Vulvovaginal Candidiasis, commonly known as vaginal yeast infections. BREXAFEMME is the first approved drug in th
SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 02'nd Jul 2021
JERSEY CITY, N.J., July 02, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resista
SCYNEXIS to Present Commercial Launch Update for BREXAFEMME® (ibrexafungerp tablets)
08:30am, Wednesday, 23'rd Jun 2021
JERSEY CITY, N.J., June 23, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resista
SCYNEXIS to Present at the BIO Digital International Convention 2021
08:30am, Friday, 11'th Jun 2021
JERSEY CITY, N.J., June 11, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resista
SCYNEXIS Confirms that BREXAFEMME® (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vaginal Yeast Infections
08:30am, Wednesday, 09'th Jun 2021
JERSEY CITY, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resista